Navigation Links
ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
Date:6/27/2011

tin, glucosuria, albuminuria and serum markers (creatinine and BUN) of renal function.  The metabolic improvements correlated with a significant reduction in adipose tissue macrophage numbers.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.

Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, CCX282 (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development.  CCX140, a CCR2 antagonist, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetes.  CCX140 is poised to enter Phase II clinical development for the treatment of diabetic nephropathy.  Other clinical programs include CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has sever
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
2. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
4. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
5. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
6. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
7. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
8. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
9. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
10. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
11. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
(Date:7/13/2014)... Wright & Schulte LLC has learned that the ... of 2015, in U.S. District Court, District of South ... process in the South Carolina federal court where ... multidistrict litigation (MDL). The complaints pending in the Louisiana ... that they took the statin medication to lower their ...
(Date:7/13/2014)... 2014 If Dr. Lawrence Power has his ... launched at http://www.HealthYourself101.com will expand people’s understanding of ... Power has set out to provide a health education platform ... – dare we say it? – entertaining to dig into ... to engage the remote learner – the solitary individual signing ...
(Date:7/12/2014)... (PRWEB) July 13, 2014 Recently, Fadhits.com, a ... collection of elegant long graduation dresses to its ... promotion for its loyal clients. It wants to bring more ... items are now offered at discounted prices, up to 72% ... company is always working hard. Its online shop is a ...
(Date:7/12/2014)... rise in the number of mobility devices around the ... suit the upsurge. Virtualization has become a growing trend ... The data traffic has increased by several folds with ... in larger and more complex networks. These global factors ... , The North American (NA) region is expected to ...
(Date:7/12/2014)... July 12, 2014 Demand Response Management ... considerable benefits in reducing the imbalance between energy supply ... appliances have been rolled out (due to increasing pressure ... (AMI). This helps in controlling residential appliances and thermostats ... in the North American region, and with government mandates ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4
... a first-of-its-kind pill to tackle heart diseases in the ... ,The company has teamed up with researchers ... the groundbreaking 'polypill' that combines four medicines including aspirin ... ,India records nearly 2.8 million deaths a year ...
... In Africa, malaria has rendered half a billion people ... is also grappling //with the largest number of HIV ... latest UN communiqué reported that 2 million people succumbed ... of Washington researchers have made a valid point in ...
... is remarkably similar to that of humans' and may hold ... of Central Florida professor Cristina Calestani and several colleagues have ... issue of Science. ,Sea urchins are small ... urchin has been used for many years as a research ...
... visitors' feet is turning into an intriguing experience at Singapore's ... spa fish, members of the garra rufa species, provide a ... the Underwater World attraction., ,The reflexologists massage the feet ... fish., ,It costs $22 for a 40-minute session for ...
... doctors predict schizophrenia, a mental disorder that affects one percent ... ,Researchers at the University of Edinburgh studied for 10 ... developing schizophrenia because two or more family members had already ... News said. ,The researchers analysed magnetic resonance imaging ...
... persons, Completely Blind, Mentally Retarded and Totally Deaf ... same person). Except Deaf & Dumb persons, concession ... Deaf & Dumb persons are eligible for concession ... granted in all Mail/Express and Super fast trains. ...
Cached Medicine News:Health News:Dr. Reddy's To Launch 'Polypill' For Treating Heart Disease 2Health News:The Deadly Duo – Why Malaria and HIV Coexist in Afric 2Health News:Sea Urchin Genome Similar To Man And May Cure Diseases 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: